BioCentury | Dec 2, 2020
Distillery Therapeutics

Blocking PCSK9 alone or with anti-PD-1 therapies for cancer

...for licensing or partneringPUBLICATION DETAILS: Liu, X. et al. Nature; published online Nov. 11, 2020doi:10.1038/s41586-020-2911-7CONTACT: Chuan-Yuan Li, Duke University Medical Center...
...Repatha (Other) Praluent (Brand), SAR236553/REGN727 (Compound #), SAR236553 (Compound #), REGN727 (Compound #), alirocumab (Generic), Praluent (Other) Duke University Medical Center Proprotein...
BioCentury | May 29, 2020
Distillery Therapeutics

Treating malaria with auphen, an inhibitor of the host membrane channel AQP3

...Pasteur, Phnom Penh, Cambodia email: bwitkowski@pasteur-kh.org CONTACT: Emily R. Derbyshire, Duke University Medical Center, Durham, N.C. email: emily.derbyshire@duke.edu Claire Quang Duke University Medical Center Institut...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

...of mammalian target of rapamycin complex 1 (mTORC1), were associated with non-response to checkpoint inhibitors Duke University Medical Center...
BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

...RIOK2) Prostate cancer Patient sample, cell line Inhibiting RIOK2 could help treat obesity-driven prostate cancer Duke University Medical Center...
BioCentury | Sep 13, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: August 2018

...studies suggest inhibiting the transient receptor potential A1 (TRPA1)-miR-711 interaction could help treat lymphoma-associated itch Duke University Medical Center...
BioCentury | Aug 8, 2018
Distillery Therapeutics

Dermatology

...Han, Q. et al. Neuron ; published online July 19, 2018 doi:10.1016/j.neuron.2018.06.039 CONTACT: Ru-Rong Ji, Duke University Medical Center...
BioCentury | Aug 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: July 2018

...a pyrazolopyrimidinone-based inhibitor of DAPK3, Pim-1 (PIM1), PIM2 and PIM3 that could help treat hypertension Duke University Medical Center...
BioCentury | Jul 24, 2018
Distillery Therapeutics

Cardiovascular

...published online July 19, 2018 doi:10.1016/j.chembiol.2018.06.006 CONTACT: Timothy A.J. Haystead, Duke University Medical Center, Durham, N.C. email: timothy.haystead@duke.edu Claire Quang Duke University Medical Center Pim-1...
BioCentury | May 5, 2018
Product Development

Rebuilding Biogen’s brain

...he headed the Neuroscience and Pain Unit. In his prior position as a professor at Duke University Medical Center...
BioCentury | Jul 25, 2017
Distillery Therapeutics

Infectious disease

...Duke University Medical Center, Durham, N.C. email: todd.bradley@duke.edu CONTACT: Barton F. Haynes, same affiliation as above email: barton.haynes@duke.edu Hongjiang Li Duke University Medical Center HIV...
Items per page:
1 - 10 of 173
BioCentury | Dec 2, 2020
Distillery Therapeutics

Blocking PCSK9 alone or with anti-PD-1 therapies for cancer

...for licensing or partneringPUBLICATION DETAILS: Liu, X. et al. Nature; published online Nov. 11, 2020doi:10.1038/s41586-020-2911-7CONTACT: Chuan-Yuan Li, Duke University Medical Center...
...Repatha (Other) Praluent (Brand), SAR236553/REGN727 (Compound #), SAR236553 (Compound #), REGN727 (Compound #), alirocumab (Generic), Praluent (Other) Duke University Medical Center Proprotein...
BioCentury | May 29, 2020
Distillery Therapeutics

Treating malaria with auphen, an inhibitor of the host membrane channel AQP3

...Pasteur, Phnom Penh, Cambodia email: bwitkowski@pasteur-kh.org CONTACT: Emily R. Derbyshire, Duke University Medical Center, Durham, N.C. email: emily.derbyshire@duke.edu Claire Quang Duke University Medical Center Institut...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

...of mammalian target of rapamycin complex 1 (mTORC1), were associated with non-response to checkpoint inhibitors Duke University Medical Center...
BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

...RIOK2) Prostate cancer Patient sample, cell line Inhibiting RIOK2 could help treat obesity-driven prostate cancer Duke University Medical Center...
BioCentury | Sep 13, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: August 2018

...studies suggest inhibiting the transient receptor potential A1 (TRPA1)-miR-711 interaction could help treat lymphoma-associated itch Duke University Medical Center...
BioCentury | Aug 8, 2018
Distillery Therapeutics

Dermatology

...Han, Q. et al. Neuron ; published online July 19, 2018 doi:10.1016/j.neuron.2018.06.039 CONTACT: Ru-Rong Ji, Duke University Medical Center...
BioCentury | Aug 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: July 2018

...a pyrazolopyrimidinone-based inhibitor of DAPK3, Pim-1 (PIM1), PIM2 and PIM3 that could help treat hypertension Duke University Medical Center...
BioCentury | Jul 24, 2018
Distillery Therapeutics

Cardiovascular

...published online July 19, 2018 doi:10.1016/j.chembiol.2018.06.006 CONTACT: Timothy A.J. Haystead, Duke University Medical Center, Durham, N.C. email: timothy.haystead@duke.edu Claire Quang Duke University Medical Center Pim-1...
BioCentury | May 5, 2018
Product Development

Rebuilding Biogen’s brain

...he headed the Neuroscience and Pain Unit. In his prior position as a professor at Duke University Medical Center...
BioCentury | Jul 25, 2017
Distillery Therapeutics

Infectious disease

...Duke University Medical Center, Durham, N.C. email: todd.bradley@duke.edu CONTACT: Barton F. Haynes, same affiliation as above email: barton.haynes@duke.edu Hongjiang Li Duke University Medical Center HIV...
Items per page:
1 - 10 of 173